Monte Rosa Therapeutics, Inc. Depreciation
Monte Rosa Therapeutics, Inc. (GLUE) reported Depreciation of $1.91 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $1.91M, a 10.07% decline year-over-year.
- Monte Rosa Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $2.03M, a 0.93% decline year-over-year.
- Monte Rosa Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $2.09M, a 1.31% increase year-over-year.
- Monte Rosa Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $2.10M, a 0.38% decline year-over-year.
- Monte Rosa Therapeutics, Inc. depreciation for fiscal 2025 was $8.36M, a 2.89% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. depreciation for fiscal 2024 was $8.12M, a 30.52% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. depreciation for fiscal 2023 was $6.22M, a 66.14% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. depreciation for fiscal 2022 was $3.75M, a 75.66% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.91M 10-Q · filed 2026-08-06 | $3.94M 10-Q · filed 2026-08-06 | $6.03M derived: sum of 3 quarters · filed 2026-08-06 | $8.12M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $2.03M 10-Q · filed 2026-05-07 | $4.12M derived: sum of 2 quarters · filed 2026-05-07 | $6.21M derived: sum of 3 quarters · filed 2026-05-07 | $8.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.18M derived: sum of 2 quarters · filed 2026-03-17 | $6.31M derived: sum of 3 quarters · filed 2026-08-06 | $8.36M 10-K · filed 2026-03-17 | |
| 2025-09-30 | $2.10M 10-Q · filed 2025-11-06 | $4.22M derived: sum of 2 quarters · filed 2026-08-06 | $6.27M 10-Q · filed 2025-11-06 | $8.33M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $2.13M 10-Q · filed 2026-08-06 | $4.17M 10-Q · filed 2026-08-06 | $6.23M derived: sum of 3 quarters · filed 2026-08-06 | $8.34M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $2.05M 10-Q · filed 2026-05-07 | $4.11M derived: sum of 2 quarters · filed 2026-05-07 | $6.21M derived: sum of 3 quarters · filed 2026-05-07 | $8.27M derived: sum of 4 quarters · filed 2026-05-07 | |
| 2024-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $4.16M derived: sum of 2 quarters · filed 2026-03-17 | $6.22M derived: sum of 3 quarters · filed 2026-03-17 | $8.12M 10-K · filed 2026-03-17 | |
| 2024-09-30 | $2.10M 10-Q · filed 2025-11-06 | $4.16M derived: sum of 2 quarters · filed 2025-11-06 | $6.06M 10-Q · filed 2025-11-06 | $7.91M derived: sum of 4 quarters · filed 2025-11-06 | |
| 2024-06-30 | $2.06M 10-Q · filed 2025-08-07 | $3.96M 10-Q · filed 2025-08-07 | $5.80M derived: sum of 3 quarters · filed 2025-08-07 | $7.64M derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $1.90M 10-Q · filed 2025-05-08 | $3.74M derived: sum of 2 quarters · filed 2025-05-08 | $5.58M derived: sum of 3 quarters · filed 2025-05-08 | $6.97M derived: sum of 4 quarters · filed 2025-05-08 | |
| 2023-12-31 | $1.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $3.68M derived: sum of 2 quarters · filed 2025-03-20 | $5.07M derived: sum of 3 quarters · filed 2025-03-20 | $6.22M 10-K · filed 2025-03-20 | |
| 2023-09-30 | $1.83M 10-Q · filed 2024-11-07 | $3.23M derived: sum of 2 quarters · filed 2024-11-07 | $4.38M 10-Q · filed 2024-11-07 | $5.45M derived: sum of 4 quarters · filed 2024-11-07 | |
| 2023-06-30 | $1.39M 10-Q · filed 2024-08-08 | $2.54M 10-Q · filed 2024-08-08 | $3.61M derived: sum of 3 quarters · filed 2024-08-08 | $4.64M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | $1.15M 10-Q · filed 2024-05-09 | $2.22M derived: sum of 2 quarters · filed 2024-05-09 | $3.25M derived: sum of 3 quarters · filed 2024-05-09 | $4.14M derived: sum of 4 quarters · filed 2024-05-09 | |
| 2022-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $2.10M derived: sum of 2 quarters · filed 2024-03-14 | $2.99M derived: sum of 3 quarters · filed 2024-03-14 | $3.75M 10-K · filed 2024-03-14 | |
| 2022-09-30 | $1.03M 10-Q · filed 2023-11-09 | $1.10M 10-Q · filed 2022-11-10 | $1.92M derived: sum of 2 quarters · filed 2023-11-09 | $2.67M 10-Q · filed 2023-11-09 | $3.48M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $889.00K 10-Q · filed 2023-08-10 | $800.00K 10-Q · filed 2022-08-11 | $1.64M 10-Q · filed 2023-08-10 | $2.45M derived: sum of 3 quarters · filed 2023-08-10 | $3.05M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $753.00K 10-Q · filed 2023-05-11 | $1.56M derived: sum of 2 quarters · filed 2023-05-11 | $2.16M derived: sum of 3 quarters · filed 2023-05-11 | $2.56M derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $809.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $1.41M derived: sum of 2 quarters · filed 2023-03-16 | $1.81M derived: sum of 3 quarters · filed 2023-03-16 | $2.13M 10-K · filed 2023-03-16 | |
| 2021-09-30 | $600.00K 10-Q · filed 2022-11-10 | $1.00M derived: sum of 2 quarters · filed 2022-11-10 | $1.32M 10-Q · filed 2022-11-10 | $1.50M derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $400.00K 10-Q · filed 2022-08-11 | $741.00K 10-Q · filed 2022-08-11 | $897.00K derived: sum of 3 quarters · filed 2022-08-11 | $1.07M derived: sum of 4 quarters · filed 2022-08-11 | |
| 2021-03-31 | $274.00K 10-Q · filed 2022-05-11 | $497.00K derived: sum of 2 quarters · filed 2022-05-11 | $668.00K derived: sum of 3 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $223.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $394.00K derived: sum of 2 quarters · filed 2022-03-29 | $537.00K 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $171.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $314.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $143.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |